| Theme | The Forefront of Hepatitis C Treatment | |
|---|---|---|
| Title | Management of Telaprevir in Combination with Peginterferon Alfa-2b and Ribavirin Therapy | |
| Publish Date | 2012/10 | |
| Author | Itaru Ozeki | Department of Gastroenterology, Sapporo Kosei General Hospital |
| [ Summary ] | Triple combination therapy employing (PegIFN, ribavirin and telaprevir) provides strong anti-HCV effects. On the other hand, the frequency of adverse events is higher with this treatment than with standard modes of treatment. It is important to modify ribavirin dosage in the early stages of treatment in order to reduce adverse reactions such as anemia, keeping blood levels within CHC treatment guidelines. To avoid serious skin rashs we must work with dermatologists as soon as possible when dermatological symptoms occur during triple combination treatment. This condition may be caused by a decline in renal function in elderly patients. There is a high probability of serious anemia or hyperuricemia with reduced renal function. |
|